Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?

Format: Webcourse
Credit(s): Informational Only
Release Date: Aug 24, 2020
Expiration Date: Jan 31, 2021
Credit Type(s):
  • Non-CME / Informational Only


Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenges, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.

This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.


Welcome and Introduction
Understanding Optimal Evaluation of Patients with NASH
Staying Up-To-Date with the Latest NASH Advances
Q&A Session


The intended audiences for this educational initiative are hepatologists and gastroenterologists involved in the assessment and management of adults with NASH.


This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Implement guideline- and expert-recommended strategies to diagnose NASH and evaluate its severity
  • Evaluate the safety and efficacy data for the NASH therapies in late-stage development


This activity is for informational purposes only.


This activity is for informational purposes only.


Stephen A Harrison, MD
Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, England
Medical Director
Pinnacle Clinical Research
San Antonio, TX
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Professor and Chairman
Department of Medicine
Inova Fairfax Medical Campus
Falls Church, VA


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.


The contents of some activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing a video.


Jointly provided by Penn State College of Medicine and Rockpointe

  Physician CME


This program is supported by educational grant from Intercept Pharmaceuticals, Inc.


Ensuring Optimal Integration of the GLP-1 Receptor Agonists: Review of the Latest Advances and Current Gaps in Care

Learn More

Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint

Learn More

Vaping and Teens: Strategies to Help Stem the Tide

Learn More

Vaping and Teens: Strategies to Help Stem the Tide

Credits 1.00 (60 min)

Format Webcourse

This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy